150mg in 1ml for administration as deep intramuscular injection every 12 weeks.
Patients > 18 years
Patients and adolescents (12-18 years), use of Sayana Press is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with Sayana Press during the critical period of bone accretion. Sayana Press has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate (MPA) in this population.
Single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection.
Licensed for self-administration. Please note company provide sharps bins BUT patients must organise safe disposal of full sharps bins via their local council.
Dose (no hormonal contraceptive use in previous month) 104 mg within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding). For long-term contraception, repeat every 13 weeks (if interval greater than 13 weeks and 7 days, rule out pregnancy before next injection)
200mg norethisterone enantate in 1ml oily solution
Noristerat®oily injection provides contraception for 8 weeks. Intended for short-term use when a high level of efficacy independent of possible errors by the patient is required. It has been licensed for short-term use by women whose partners undergo vasectomy, until the vasectomy is effective, and women immunised against rubella, to prevent pregnancy during the period of activity of the virus.
Non Formulary Items
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
High Cost Drug Approval System
Traffic Light Status Information
RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.
Amber medicines are considered suitable for GP prescribing following specialist initiation or recommendation.
Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.
These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations.
Suitable for patient to be directed to buy themselves
Not currently used. We intend to include this TLS in future to highlight where a decision to use this medicine is under review.
(In use from Oct 2020) Used where a decision has been made by the BSW APC not to routinely commission this preparation for its licensed indications. Do not prescribe.
Not currently used. We intend to include this TLS in future to highlight where this medicine and indication is ONLY available through a Specialist Centre according to a NICE Highly Specialised Technology or NHSE Specialised Commission Circular / Policy.